Charles River Laboratories International, Inc. (NYSE: CRL) announced that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share. HemaCare will become part of Charles River’s Research Models and Services segment. HemaCare is a leader in the production of human-derived cellular products for the cell therapy market.
Read the full article: Charles River Laboratories Completes the Acquisition of HemaCare Corporation //
Source: https://www.businesswire.com/news/home/20200103005194/en/Charles-River-Laboratories-Completes-Acquisition-HemaCare-Corporation